Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
18,505,347
-
Total 13F shares
-
6,656,933
-
Share change
-
+5,885,831
-
Total reported value
-
$63,199,568
-
Price per share
-
$9.50
-
Number of holders
-
28
-
Value change
-
+$55,874,127
-
Number of buys
-
12
-
Number of sells
-
3
Institutional Holders of Avalo Therapeutics, Inc. - Common Stock, par value $0.001 per share (AVTX) as of Q3 2024
As of 30 Sep 2024,
Avalo Therapeutics, Inc. - Common Stock, par value $0.001 per share (AVTX) was held by
28 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,656,933 shares.
The largest 10 holders included
Ikarian Capital, LLC, RA CAPITAL MANAGEMENT, L.P., ORBIMED ADVISORS LLC, Deep Track Capital, LP, BVF INC/IL, Logos Global Management LP, COMMODORE CAPITAL LP, TCG Crossover Management, LLC, BOOTHBAY FUND MANAGEMENT, LLC, and Sio Capital Management, LLC.
This page lists
28
institutional shareholders reporting positions in this security
for the Q3 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.